Novo Nordisk Opens the Door to Peptide API Outsourcing: 10x Oral Wegovy Patient Target by 2030 Hands Peptide CDMOs a Historic Order Window
Novo Nordisk said at its Capital Markets Day that it will use CMOs for peptide API synthesis — a major break from its decades-long vertically integrated model. Macquarie estimates that switching from injectable to oral formulation can raise per-patient peptide API demand roughly 73-fold, while Novo targets a tenfold rise in oral Wegovy patients to 15 million by 2030. WuXi AppTec, Samsung Biologics and Divi's Labs are flagged as potential beneficiaries as the peptide CDMO race shifts to a dual contest of cost and delivery certainty.
The world's largest GLP-1 drugmaker is quietly rewriting its supply-chain rules. At its recent Capital Markets Day, Novo Nordisk announced it will use contract manufacturing organizations (CMOs) for peptide API synthesis — a significant pivot for a company famous for vertical integration, whose external partnerships were historically confined to fill-finish, packaging and device assembly while API production stayed in-house. Macquarie called the move a significant shift in Novo's long-standing model, one that reinforces the investment case for peptide CDMOs worldwide.
Why now: oral formulations multiply API demand up to 73-fold
The driver is the capacity arithmetic of oral GLP-1s. Oral peptide formulations have far lower bioavailability than injectables and require multiples more API to compensate — Macquarie's illustration: moving from injectable Wegovy to an oral formulation could raise annual peptide API needs per patient by about 73 times. Novo, meanwhile, targets roughly a tenfold rise in its oral Wegovy patient base by 2030 (from about 1.5 million to 15 million) and is investing EUR 432M to upgrade its Athlone, Ireland plant for oral GLP-1 production. The math is straightforward: even partial delivery of that growth creates an API demand gap that in-house capacity alone cannot fill. Macquarie puts Novo's share of the global GLP-1 market at about 51% by volume and 37% by value in H1 2026 — its sourcing decisions alone can reshape the outsourcing landscape.
Who catches the door: three candidates and one critical variable
Macquarie assessed three categories of beneficiaries: WuXi AppTec — arguably the largest manufacturing scale among current peptide CDMOs, with TIDES revenue up 44.3% YoY in H1 and an integrated discovery-to-commercial chain; Divi's Laboratories — standing out for deep vertical integration (many self-made intermediates and starting materials), whose cost control aligns with Novo's selection criteria, making it Macquarie's top India pick; Samsung Biologics — a dark horse that entered peptide APIs through the PolyPeptide acquisition and can offer combined biologics + peptide delivery on top of its 845,000 L biologics base. One critical variable runs through the report: cost. Novo management reiterated at CMD that fermentation-based peptide API remains the lowest-cost route and that its own scale and continuous manufacturing confer cost advantages — so manufacturing economics, alongside quality, regulatory track record and reliability, will be the decisive selection criteria.
Editorial view: from a capacity arms race to a contest of cost and certainty
For two years the peptide CDMO story has been a capacity arms race: Asymchem plans 69,000 L of peptide capacity by end-2026, SK pharmteco has pledged over US$200M to expand US peptide capacity, Eli Lilly broke ground on a US$6.5B API facility for its oral candidate, and Samsung Biologics simply bought PolyPeptide. Now that the demand side itself has opened the outsourcing door, the axis of competition is shifting: capacity scarcity gives way to unit cost and the certainty of at-scale delivery. For Chinese peptide CDMOs this is a two-sided signal. The upside: the world's biggest peptide buyer is, for the first time, a potential incremental customer, and Chinese players are deeply versed in both solid-phase synthesis and fermentation routes. The caution: Macquarie notes that almost all leading peptide CDMOs already serve Eli Lilly, Novo's arch-rival — meaning competitive and supply-security considerations will inevitably be layered into vendor selection. The order window is open, but only the players with the steepest cost curve and proven multi-continent compliance delivery will catch it.
FAQ
Why is Novo Nordisk outsourcing peptide API production?
Oral GLP-1 drugs such as oral Wegovy have far lower bioavailability than injectables, raising per-patient peptide API demand by roughly 73 times. With Novo targeting a tenfold expansion of its oral Wegovy patient base to about 15 million by 2030, in-house capacity alone cannot close the gap — hence the Capital Markets Day pivot to CMO-sourced peptide APIs.
Which CDMOs are most likely to benefit?
Macquarie assessed WuXi AppTec (among the largest peptide manufacturing scale with an integrated TIDES chain), India's Divi's Laboratories (deep vertical integration and cost control, Macquarie's top India pick), and Samsung Biologics (a dark horse with combined biologics + peptide capability after acquiring PolyPeptide). Manufacturing economics, quality and regulatory track record are the core vendor-selection criteria.
What does this mean for Chinese peptide CDMOs?
The world's largest GLP-1 buyer opening peptide API procurement to external CMOs validates the long-term growth of peptide outsourcing and shifts competition from capacity scale to unit cost and delivery certainty. Chinese players have deep expertise across synthesis routes, but must also navigate the reality that leading CDMOs are broadly already bound to Eli Lilly, adding competitive and supply-security considerations to Novo's selection.